ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis

In the article published by Zhou et al. [ [1] Zhou Y. Jiang W. Zeng L. et al. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab. Lung Cancer. 2020; 143: 55-59 Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar ], it was identified a novel ROS1 mutation type namely G2032 K in which mediated resistance to targeted therapy like lorlatinib in lung adenocarcinoma. They suggested that immune checkpoint inhibitors (ICIs) plus chemotherapy could be considered as an option for patients harboring ROS1 mutations after acquired resistance to targeted therapies. Nevertheless, it was unknown whether the patient with ROS1 mutations would obtain clinical benefit from ICIs treatment alone. A reply to “ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis”Lung CancerVol. 150PreviewWe would like to thank Xuanzong Li and colleagues for their interest in our recent publication entitled” A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab” [1]. The primary focus of our study was to investigate whether the secondary ROS1 G2032 K substitution we identified at progression from lorlatinib affected the binding of lorlatinib and led to lorlatinib resistance. With the lack of targeted therapeutic options after lorlatinib resistance, chemotherapy plus pembrolizumab was administered as fifth-line regimen that benefitted our patient. Full-Text PDF